AEGLEA BIOTHERAPEUTICS
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that address rare genetic diseases.
AEGLEA BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2013-01-01
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.aeglea.com
Total Employee:
101+
Status:
Active
Contact:
+1 512 942 2935
Email Addresses:
[email protected]
Total Funding:
266 M USD
Technology used in webpage:
HSTS IPv6 ReCAPTCHA V2 ASP.NET Ajax Google Analytics IP Anonymization YourAdChoices.com Q4Web
Similar Organizations
Alethia BioTherapeutics
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Rezolute
Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Molecular Templates
Molecular Templates develops novel therapeutic compounds for cancer.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-06-22 | Spyre Therapeutics | Spyre Therapeutics acquired by Aeglea BioTherapeutics | N/A |
Investors List
UT Horizon Fund
UT Horizon Fund investment in Series B - Aeglea BioTherapeutics
Lilly Ventures
Lilly Ventures investment in Series B - Aeglea BioTherapeutics
Rock Springs Capital
Rock Springs Capital investment in Series B - Aeglea BioTherapeutics
Jennison Associates
Jennison Associates investment in Series B - Aeglea BioTherapeutics
Ally Bridge Group
Ally Bridge Group investment in Series B - Aeglea BioTherapeutics
OrbiMed
OrbiMed investment in Series B - Aeglea BioTherapeutics
Venrock
Venrock investment in Series B - Aeglea BioTherapeutics
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - Aeglea BioTherapeutics
New Ground Ventures
New Ground Ventures investment in Series B - Aeglea BioTherapeutics
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Aeglea BioTherapeutics
Official Site Inspections
http://www.aeglea.com Semrush global rank: 13.27 M Semrush visits lastest month: 78
- Host name: afa7f374f51cc8991.awsglobalaccelerator.com
- IP address: 3.33.186.135
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Aeglea BioTherapeutics"
Aeglea BioTherapeutics - Crunchbase Company Profile & Funding
Organization. Aeglea BioTherapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Aeglea BioTherapeutics is a …See details»
Aeglea BioTherapeutics Announces Update to Corporate Structure …
Jan 6, 2023 Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill, M.B.A., has been promoted to …See details»
Aeglea BioTherapeutics Inc. - Company Overview
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited …See details»
Aeglea BioTherapeutics - Org Chart, Teams, Culture & Jobs - The …
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases …See details»
Aeglea Company Profile - Office Locations, Competitors, Revenue …
Jan 29, 2024 Aeglea has 5 employees at their 1 location and $886 k in annual revenue in FY 2023. See insights on Aeglea including office locations, competitors, revenue, financials, …See details»
Aeglea BioTherapeutics - Contacts, Employees, Board Members, …
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases. ... Solutions. Products. Resources. Pricing. Resources. …See details»
Aeglea BioTherapeutics - Funding, Financials, Valuation & Investors
Aeglea BioTherapeutics is registered under the ticker NASDAQ:AGLE . Their stock opened with $10.00 in its Apr 7, 2016 IPO. Aeglea BioTherapeutics is funded by 12 investors. UT Horizon …See details»
Aeglea BioTherapeutics Announces Update to Corporate Structure …
Jan 6, 2023 Aeglea is investigating pegtarviliase in an ongoing Phase 1/2 clinical trial for the treatment of Classical Homocystinuria. Pegtarviliase has been granted Rare Pediatric Disease …See details»
Aeglea BioTherapeutics Expands Executive Leadership Team with ...
Sep 5, 2023 Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of …See details»
Aeglea BioTherapeutics - PitchBook
Aeglea BioTherapeutics General Information Description. Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease …See details»
Aeglea BioTherapeutics Inc. - Aeglea BioTherapeutics Corporate …
Jan 13, 2021 At Aeglea BioTherapeutics Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor …See details»
Aeglea BioTherapeutics - LinkedIn
Aeglea BioTherapeutics | 9,965 followers on LinkedIn. With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best …See details»
Aeglea BioTherapeutics Inc. - Aeglea BioTherapeutics Announces ...
Aug 24, 2022 Prioritizing Resources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2 Trial in Homocystinuria with Interim Clinical Data Expected in Q4 of 2022 …See details»
Aeglea BioTherapeutics Announces Update to Corporate Structure …
Jan 6, 2023 Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creationCortney Caudill, M...See details»
Aeglea BioTherapeutics Announces Leadership Transition and …
Aug 24, 2022 Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with …See details»
Aeglea lays off more staff, seeks exit in face of rocky data
Apr 12, 2023 At the time, Aeglea framed the changes as a way to streamline the organization and maximize the value of its two clinical programs, pegtarviliase and pegzilarginase.See details»
Aeglea BioTherapeutics Inc. - Aeglea BioTherapeutics Reports …
AUSTIN, Texas, March 18, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme …See details»
Working at Aeglea BioTherapeutics - Zippia
Mar 14, 2024 Zippia gives an in-depth look into the details of Aeglea BioTherapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about …See details»
Aeglea BioTherapeutics Announces Update to Corporate
Jan 6, 2023 Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation. Cortney Caudill, M.B.A., has been promoted to …See details»
Financials - Annual Reports and Proxy - Aeglea
At Aeglea BioTherapeutics Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are …See details»